Anaplastic glioma: Standards and new developments in diagnostics and therapy

被引：0

作者：

Wick W. ^{[1
,5
]}

Von Deimling A. ^{[2
]}

Grabenbauer G.G. ^{[3
]}

Westphal M. ^{[4
]}

机构：

[1] Zentrum Neurologie, Universität Tübingen

[2] Institut für Neuropathologie, Charité, Universitätsmedizin Berlin

[3] Strahlenklinik, Universität Erlangen-Nürnberg

[4] Neurochirurgische Klinik, Universitätsklinikums Hamburg Eppendorf

[5] Zentrum Neurologie, Universität Tübingen, 72076 Tübingen

来源：

Der Onkologe | 2006年 / 12卷 / 6期

关键词：

Anaplastic gliomas; LOH; 1p/19q; Molecular diagnostics; Radiochemotherapy; Temozolomide;

D O I：

10.1007/s00761-006-1068-9

中图分类号：

学科分类号：

摘要：

Recent developments in molecular diagnostics, especially the determination of a beneficial impact of the loss of heterozygosity (LOH) on chromosomes 1p and 19q, are influencing scientific and clinical studies on anaplastic glioma. Results from the new EORTC 26951 and RTOG 9402 studies imply the differentiation of tumors with and without LOH 1p/19q in the near future. This review discusses the state of the art in imaging, surgery, and the radio- as well as chemotherapy of anaplastic gliomas. Future concepts for an evaluation of radiochemotherapy with temozolomide for anaplastic gliomas without LOH 1p/19q, and analysis of the relevance of this combined modality treatment on overall survival, are outlined. The therapeutic challenge for anaplastic gliomas with a better prognosis (with LOH 1p/19q) is the identification of an experimental study arm that allows a prolongation of overall and not just progression-free survival in this patient cohort. © Springer Medizin Verlag 2006.

引用

页码：508 / 517

页数：9

共 36 条

[1]

Allison R.R., Schulsinger A., Vongtama V., Et al., Radiation and chemotherapy improve outcome in oligodendroglioma, Int J Radiat Oncol Biol Phys, 37, pp. 399-403, (1997)

[2]

Brada M., Sharpe G., Rajan B., Et al., Modifying radical radiotherapy in high grade gliomas

[3]

shortening the treatment time through acceleration, Int J Radiat Oncol Biol Phys, 43, pp. 287-292, (1999)

[4]

Cairncross J.G., Macdonald D., Ludwin S., Et al., Chemotherapy for anaplastic oligodendroglioma, J Clin Oncol, 12, pp. 2013-2021, (1994)

[5]

Cairncross J.G., Seiferheld E., Shaw R., Et al., An intergroup randomized controlled trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94 - 02, J Clin Oncol, 22, (2004)

[6]

Cairncross J.G., Ueki K., Zlatescu M.C., Et al., Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, 90, pp. 1473-1479, (1998)

[7]

Chan J.L., Lee S.W., Fraass B.A., Et al., Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy, J Clin Oncol, 20, pp. 1635-1642, (2002)

[8]

Chinot O.L., Honore S., Dufour H., Et al., Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy, J Clin Oncol, 19, pp. 2449-2455, (2001)

[9]

Davis F.G., McCarthy B.J., Freels S., Et al., The conditional probability of survival of patients with primary malignant brain tumors. Surveillance, epidemiology, and end results (SEER) data, Cancer, 85, pp. 485-491, (1999)

[10]

Do V., Gebski V., Barton M.B., The effect of waiting for radiotherapy for grade III/IV gliomas, Radiother Oncol, 57, pp. 131-136, (2000)

← 1 2 3 4 →